S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals Stock Forecast, Price & News

$0.95
-0.09 (-8.65 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.95
Now: $0.95
$1.10
50-Day Range
$0.57
MA: $0.66
$0.73
52-Week Range
$0.24
Now: $0.95
$1.94
Volume5.18 million shs
Average Volume5.22 million shs
Market Capitalization$39.69 million
P/E RatioN/A
Dividend YieldN/A
Beta3.5
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NovaBay Pharmaceuticals logo

MarketRank

Overall MarketRank

0.65 out of 5 stars

Medical Sector

1255th out of 1,926 stocks

Pharmaceutical Preparations Industry

573rd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800
Employees26
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.60 million
Book Value$0.03 per share

Profitability

Net Income$-9,650,000.00
Net Margins-122.78%

Miscellaneous

Market Cap$39.69 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable
$0.95
-0.09 (-8.65 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What stocks does MarketBeat like better than NovaBay Pharmaceuticals?

Wall Street analysts have given NovaBay Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovaBay Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for NovaBay Pharmaceuticals
.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. The biopharmaceutical company earned $2.17 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 122.78% and a negative trailing twelve-month return on equity of 309.15%.
View NovaBay Pharmaceuticals' earnings history
.

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals's stock reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

Who are some of NovaBay Pharmaceuticals' key competitors?

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the following people:
  • Mr. Justin M. Hall Esq., Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director (Age 43, Pay $325.72k)
  • Mr. Andrew D. Jones, CFO & Treasurer
  • Ms. Wang Xu, Sr. Mang. & Controller (Age 38)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.95.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $39.69 million and generates $6.60 million in revenue each year. The biopharmaceutical company earns $-9,650,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. NovaBay Pharmaceuticals employs 26 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is novabay.com.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.